Myonexus Therapeutics Receives FDA Orphan Drug Designation for LGMD Type 2E Treatment

By on

Myonexus Therapeutics Receives FDA Orphan Drug Designation for LGMD Type 2E Treatment

Myonexus Therapeutics Receives FDA Orphan Drug Designation for LGMD Type 2E Treatment